Long-Acting HIV Therapy Demonstrates Superior Viral Suppression in CROWN Trial

A phase 3b clinical trial, CROWN, found that long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression compared to daily oral antiretroviral therapy (ART) over six months. This outcome, observed in treatment-experienced adults and adolescents with HIV, is a significant advancement, particularly for individuals struggling with adherence to daily oral regimens, potentially improving treatment outcomes and quality of life.